Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow Transplantation

Phase 2

Completed

Conditions: Leukemia
Graft Versus Host Disease
Myelodysplastic Syndromes

First Posted Date: 2003-05-09

Last Posted Date: 2013-07-10

Lead Sponsor: Chimeric Therapies

Registration Number: NCT00004255

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Shands Hospital and Clinics, University of Florida, Gainesville, Florida, United States
🇺🇸
Presbyterian-St Luke's Medical Center, Denver, Colorado, United States

and more 12 locations

Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia

Phase 2

Completed

Conditions: T-Cell Prolymphocytic Leukemia
B-Cell Prolymphocytic Leukemia
Prolymphocytic Leukemia
Recurrent Chronic Lymphocytic Leukemia
Refractory Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Recurrent Small Lymphocytic Lymphoma

Interventions: Drug: Cyclosporine
Drug: Fludarabine Phosphate
Procedure: Hematopoietic Cell Transplantation
Other: Laboratory Biomarker Analysis
Drug: Mycophenolate Mofetil
Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Radiation: Total-Body Irradiation

First Posted Date: 2003-05-07

Last Posted Date: 2017-12-08

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 21

Registration Number: NCT00060424

Locations: 🇺🇸
Veterans Administration Center-Seattle, Seattle, Washington, United States
🇮🇹
University of Torino, Torino, Italy
🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Stem Cell Transplant for Hematologic Diseases

Phase 1

Terminated

Conditions: Hematologic Malignancies

Interventions: Biological: Campath 1H
Drug: Fludarabine
Procedure: Stem Cell Transplant
Radiation: Total Body Irradiation (TBI)
Drug: FK506 (Tacrolimus) or Cyclosporine

First Posted Date: 2003-04-15

Last Posted Date: 2016-11-06

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 27

Registration Number: NCT00058825

Locations: 🇺🇸
The Methodist Hospital, Houston, Texas, United States
🇺🇸
Texas Children's Hospital, Houston, Texas, United States

Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma

Phase 1

Completed

Conditions: B-cell Chronic Lymphocytic Leukemia
Contiguous Stage II Grade 1 Follicular Lymphoma
Contiguous Stage II Grade 2 Follicular Lymphoma
Contiguous Stage II Mantle Cell Lymphoma
Contiguous Stage II Marginal Zone Lymphoma
Contiguous Stage II Small Lymphocytic Lymphoma
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Nodal Marginal Zone B-cell Lymphoma
Noncontiguous Stage II Grade 1 Follicular Lymphoma
Noncontiguous Stage II Grade 2 Follicular Lymphoma

Interventions: Drug: alvocidib
Drug: fludarabine phosphate
Biological: rituximab
Other: pharmacological study

First Posted Date: 2003-04-09

Last Posted Date: 2013-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 37

Registration Number: NCT00058227

Locations: 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States

Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases

Phase 1

Completed

Conditions: Hematologic Malignancy

Interventions: Drug: ANTI-CD45
Drug: CAMPATH-1H
Drug: FK506
Drug: Fludarabine
Radiation: Total Body Irradiation
Procedure: Stem cell infusion

First Posted Date: 2003-03-27

Last Posted Date: 2012-06-29

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 24

Registration Number: NCT00056966

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇺🇸
The Methodist Hospital, Houston, Texas, United States

Monoclonal Antibody Conditioning for Allogeneic Stem Cell Transplantation of Patients With Inherited Metabolic Storage Diseases

Phase 1

Terminated

Conditions: Inherited Metabolic Storage Diseases

Interventions: Drug: CAMPATH-1H
Drug: Anti-CD45
Drug: FK506
Drug: Fludarabine

First Posted Date: 2003-03-27

Last Posted Date: 2015-09-23

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 2

Registration Number: NCT00056979

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇺🇸
The Methodist Hospital, Houston, Texas, United States

Allogeneic Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer

Phase 2

Completed

Conditions: Kidney Cancer

Interventions: Procedure: allogeneic bone marrow transplantation
Biological: therapeutic allogeneic lymphocytes
Procedure: peripheral blood stem cell transplantation
Drug: cyclophosphamide
Drug: cyclosporine
Drug: fludarabine phosphate

First Posted Date: 2003-03-07

Last Posted Date: 2021-02-24

Lead Sponsor: UNICANCER

Target Recruit Count: 57

Registration Number: NCT00056095

Locations: 🇫🇷
Centre Paul Papin, Angers, France
🇫🇷
Centre Hospitalier Regional de Besancon - Hopital Jean Minjoz, Besancon, France
🇫🇷
Centre Hospitalier Regional et Universitaire d'Angers, Angers, France

and more 23 locations

Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders

Phase 2

Completed

Conditions: Leukemia
Lymphoma
Myelodysplastic Syndromes
Myelodysplastic-Myeloproliferative Diseases

First Posted Date: 2003-03-07

Last Posted Date: 2011-03-07

Lead Sponsor: Roswell Park Cancer Institute

Registration Number: NCT00055653

Locations: 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Children's Hospital of Orange County, Orange, California, United States
🇺🇸
North Shore University Hospital, Manhasset, New York, United States

and more 22 locations

Reduced-Intensity Conditioning Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma

Phase 1

Completed

Conditions: Refractory Multiple Myeloma

Interventions: Drug: fludarabine phosphate
Drug: melphalan
Radiation: total-body irradiation
Drug: mycophenolate mofetil
Drug: cyclosporine
Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation
Other: laboratory biomarker analysis

First Posted Date: 2003-02-06

Last Posted Date: 2017-10-16

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 16

Registration Number: NCT00054353

Locations: 🇮🇹
University of Torino, Torino, Italy
🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders

Phase 2

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Diseases
Chronic Myeloproliferative Disorders
Fanconi Anemia
Aplastic Anemia
Leukemia
Lymphoma

Interventions: Biological: anti-thymocyte globulin
Biological: graft-versus-tumor induction therapy
Biological: sargramostim
Biological: therapeutic allogeneic lymphocytes
Drug: cyclophosphamide
Drug: fludarabine phosphate
Drug: methylprednisolone
Drug: mycophenolate mofetil
Drug: tacrolimus
Procedure: allogeneic bone marrow transplantation
Procedure: peripheral blood stem cell transplantation
Procedure: umbilical cord blood transplantation

First Posted Date: 2003-02-06

Last Posted Date: 2020-02-10

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 41

Registration Number: NCT00053989

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy